[{"id":"23cc0738-3191-4a02-95c6-0041a5970bd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05866692","created_at":"2023-05-19T13:04:54.015Z","updated_at":"2024-07-02T16:35:30.316Z","phase":"Phase 1","brief_title":"A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05866692","lead_sponsor":"TYK Medicines, Inc","biomarkers":" HER-2 • PD-L1 • KRAS • ER • BRCA","pipe":" | ","alterations":" KRAS mutation • HER-2 negative • ER negative • BRCA mutation • PGR expression","tags":["HER-2 • PD-L1 • KRAS • ER • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HER-2 negative • ER negative • BRCA mutation • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY-2699a"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 08/17/2023","start_date":" 08/17/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-11-06"}]